Martin Hunt

Président chez SKINBIOTHERAPEUTICS PLC Fortune : 72 905 $ au 31/05/2026

Profil

Martin Braddock Hunt currently works at Videregen Ltd., as Chairman, SkinBioTherapeutics Plc, as Executive Chairman from 2026, i4i LP, as Programme Director, Invictus Management Ltd., as Director, and National Institute For Health & Care Research, as Programme Director.
Mr. Hunt also formerly worked at Tissue Science Laboratories Ltd., as Chief Executive Officer, MDY Healthcare Ltd., as Deputy Chairman, Trophos SA, as Vice Chairman-Supervisory Board, Wyeth Holdings LLC, as Marketing Director-Europe, Middle East & Africa, ArcticZymes Technologies ASA, as Director, DYSIS Medical Ltd., as Director in 2012, Tissue Science Laboratories (UK) Ltd., as Director, Regentix Ltd., as Director, Orthox Ltd., as Non-Executive Director, and Bristol Myers Squibb Co., as Vice President-Europe Sales from 1994 to 1996.

Détentions connues dans des sociétés publiques

Société	Date	Nombre d'actions	Valorisation	Date de valorisation
SKINBIOTHERAPEUTICS PLC 0,22 %	30/06/2025	560 417 ( 0,22 % )	72 905 $	31/05/2026

Postes actifs de Martin Hunt

Sociétés	Poste	Début
SKINBIOTHERAPEUTICS PLC	Président	03/10/2016
Invictus Management Ltd.	Directeur/Membre du Conseil	13/12/2010
National Institute For Health & Care Research	Corporate Officer/Principal	-
i4i LP	Corporate Officer/Principal	-
Videregen Ltd.	Président	-

Anciens postes connus de Martin Hunt

Sociétés	Poste	Fin
Tissue Science Laboratories (UK) Ltd.	Directeur/Membre du Conseil	-
ARCTICZYMES TECHNOLOGIES ASA	Directeur/Membre du Conseil	-
Trophos SA	Directeur/Membre du Conseil	-
DYSIS Medical Ltd.	Président	-
░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░	░░░░░░░░░ ░░░░░░░░░░░░░░░░░	-